JP5033789B2 - 腎臓機能分析のための方法 - Google Patents
腎臓機能分析のための方法 Download PDFInfo
- Publication number
- JP5033789B2 JP5033789B2 JP2008507811A JP2008507811A JP5033789B2 JP 5033789 B2 JP5033789 B2 JP 5033789B2 JP 2008507811 A JP2008507811 A JP 2008507811A JP 2008507811 A JP2008507811 A JP 2008507811A JP 5033789 B2 JP5033789 B2 JP 5033789B2
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- animal
- rate
- molecular
- determining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 78
- 230000003907 kidney function Effects 0.000 title description 8
- 238000004458 analytical method Methods 0.000 title description 4
- 238000001914 filtration Methods 0.000 claims description 50
- 210000003734 kidney Anatomy 0.000 claims description 37
- 241001465754 Metazoa Species 0.000 claims description 34
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 239000008280 blood Substances 0.000 claims description 27
- 230000024924 glomerular filtration Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 12
- 230000037323 metabolic rate Effects 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- 230000009102 absorption Effects 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- QUTFFEUUGHUPQC-ILWYWAAHSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC1=CC=C([N+]([O-])=O)C2=NON=C12 QUTFFEUUGHUPQC-ILWYWAAHSA-N 0.000 claims description 2
- DEPMSUUWSGUYKQ-IWXIMVSXSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanal Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CNC1=CC=C([N+]([O-])=O)C2=NON=C12 DEPMSUUWSGUYKQ-IWXIMVSXSA-N 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000010287 polarization Effects 0.000 claims description 2
- 230000009103 reabsorption Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 230000007102 metabolic function Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 description 45
- 238000005259 measurement Methods 0.000 description 35
- 230000006870 function Effects 0.000 description 25
- 239000008103 glucose Substances 0.000 description 24
- 239000007850 fluorescent dye Substances 0.000 description 22
- 239000013307 optical fiber Substances 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000003745 diagnosis Methods 0.000 description 14
- 210000002700 urine Anatomy 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 201000001474 proteinuria Diseases 0.000 description 10
- 238000012545 processing Methods 0.000 description 9
- 229920001202 Inulin Polymers 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 230000004153 glucose metabolism Effects 0.000 description 8
- 229940029339 inulin Drugs 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 150000002605 large molecules Chemical class 0.000 description 6
- 229920002521 macromolecule Polymers 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000005286 illumination Methods 0.000 description 5
- 230000013878 renal filtration Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000036267 drug metabolism Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 150000002303 glucose derivatives Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- GZCGUPFRVQAUEE-VANKVMQKSA-N aldehydo-L-glucose Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-VANKVMQKSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- -1 2-oxa-1,3-diazol-4-yl Chemical group 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100518359 Homo sapiens RHO gene Proteins 0.000 description 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000001444 catalytic combustion detection Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960002761 levoglucose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000005234 proximal tubule cell Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Description
詳細な説明では、下記の図面が特に参照される。
Claims (18)
- 動物中の臓器による第1の分子の身体区画クリアランスの速度定数(k)を求める方法であって、
身体区画において、前記第1の分子が前記臓器によって前記身体区画から除去される速度よりも低い速度で、前記臓器によって前記身体区画から除去される第2の分子に対する、前記第1の分子の分子比(RB/RA)の時系列((RB/RA)(t))を得るために、前記分子比(RB/RA)をある長さの時間にわたって求める工程であって、前記分子比(RB/RA)は、下記の式:
RB/RA = IB/IA
(式中、IBは身体区画中の第1の分子のレベルであり、IAは身体区画中の第2の分子のレベルである)
を用いて求められる工程、及び、
下記の式:
(RB/RA)(t) = c + a * exp(-kt)
(式中、cは定数であり、aは前指数係数であり、tは時間である)
を用いて身体区画クリアランスの速度定数(k)を求めるために、分子比の時系列((RB/RA)(t))の最小二乗近似を行う工程
を含む方法。 - 前記身体区画が前記動物の血管系であることを特徴とする、請求項1に記載の方法。
- 前記臓器が、腎臓,肝臓,肺,脾臓,膵臓,脳,心臓,筋,及び腸から成るグループから選ばれることを特徴とする、請求項1に記載の方法。
- 前記臓器の身体区画クリアランスが、濾過,再吸収,浸透,代謝,及び能動的分泌の少なくとも一つによることを特徴とする、請求項1に記載の方法。
- 前記第1の分子のレベルが、前記第1の分子によって生じたシグナルの強度に基づいて求められ、前記第2の分子のレベルが、前記第2の分子によって生じたシグナルの強度に基づいて求められることを特徴とする、請求項1に記載の方法。
- 前記第1の分子によって生じたシグナルが、前記第2の分子によって生じたシグナルとは異なるタイプのシグナルであることを特徴とする、請求項5に記載の方法。
- 前記第1の分子によって生じたシグナルと前記第2の分子によって生じたシグナルが、蛍光,入射光からの散乱シグナル,蛍光寿命の割合,吸収,及び偏光から成るグループから選ばれることを特徴とする、請求項5に記載の方法。
- 前記第1の分子の前記第2の分子に対する分子比(RB/RA)が、前記第1の分子と前記第2の分子の一般化極性(GP)によって置き換えられ、前記一般化極性(GP)は、下記の式:
GP = (IA - IB)/(IA + IB)
および
GP = (IB - IA)/(IA + IB)
(式中、IAは血液中の第2の分子のレベルであり、IBは血液中の第1の分子のレベルである)
から成るグループから選ばれる式によって求められることを特徴とする、請求項1に記載の方法。 - 前記臓器の糸球体濾過率(GFR)を、下記の式:
GFR = (k * Vplasma) / ξ
(式中、Vplasmaは前記動物の総血漿体積であり、ξは前記第1の分子の分子濾過抵抗である)
を用いて求める工程をさらに含み、前記臓器は腎臓であることを特徴とする、請求項1に記載の方法。 - 前記第1の分子の分子濾過抵抗が、約1の値を有することを特徴とする、請求項9に記載の方法。
- 前記第2の分子が、70kDを越える分子量を有する蛍光標識分子であることを特徴とする、請求項10に記載の方法。
- 前記第2の分子が、前記第1の分子よりも大きい分子量を有することを特徴とする、請求項10に記載の方法。
- 動物中の分子の分子濾過抵抗(ξ)を求める方法であって、
請求項10に記載の方法によって、前記動物の糸球体濾過率(GFR)を求める工程、
請求項1に記載の方法によって、前記動物の身体区画クリアランス(k2)の速度定数を求める工程であって、前記分子は前記第1の分子である工程、及び、
下記の式:
ξ = (k2 * Vplasma)/GFR
(式中、Vplasmaは動物の総血漿体積である)
を用いて、前記分子の分子濾過抵抗(ξ)を求める工程、
を含む方法。 - 前記分子がタンパク質であることを特徴とする、請求項14に記載の方法。
- 動物中の試験分子の代謝速度を求める方法であって、
請求項1に記載の方法によって、前記動物の血管に投与された、臓器によって代謝されない第1の分子の身体区画クリアランスの速度定数(k1)を求める工程、
前記動物の血管に投与された試験分子の前記動物の血管に投与された第2の分子に対する分子比(RC/A)の時系列((RC/A)(t))を得るために、ある長さの時間にわたって前記試験分子の前記第2の分子に対する分子比を求める工程、及び、
下記の式:
(RC/A)(t) = c + a * exp(-k1t) + M(km,t)
(式中、cは定数であり、k1は第1の分子のクリアランスの速度定数であり、aは前指数係数であり、tは時間である)
に従って試験分子の代謝関数(M(km,t))を求めるために、前記試験分子の前記第2の分子に対する分子比の時系列((RC/A)(t))の最小二乗近似を行う工程、
を含む方法。 - 代謝関数(M(km,t))が、下記の式:
M(km,t) = (RC/A)(t) - (RB/A)(t) = (IC(t) - IB(t))/IA(t)
(式中、(RC/A)(t)は前記試験分子の前記第2の分子に対する分子比の時系列であり、(RB/A)(t)は前記第1の分子の前記第2の分子に対する分子比の時系列であり、IC(t)は血液中の前記試験分子のレベルの時系列であり、IB(t)は血液中の前記第1の分子のレベルの時系列であり、IA(t)は血液中の前記第2の分子のレベルの時系列である)
に従って求められることを特徴とする、請求項15に記載の方法。 - 前記試験分子が、D−グルコースの代謝性アナログであって、且つ、前記代謝速度が、D−グルコースの代謝速度であることを特徴とする、請求項15に記載の方法。
- 前記D−グルコースの代謝性アナログが、[2−(N−(7−ニトロベンゾ−2−オキサ−1,3−ジアゾール−4−イル)アミノ)−2−デオキシグルコース](2−NBDG)、または[6−(N−(7−ニトロベンゾ−2−オキサ−1,3−ジアゾール−4−イル)アミノ)−2−デオキシグルコース](6−NBDG)であることを特徴とする、請求項17に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67270805P | 2005-04-19 | 2005-04-19 | |
US60/672,708 | 2005-04-19 | ||
PCT/US2006/014576 WO2006113724A1 (en) | 2005-04-19 | 2006-04-18 | Method and apparatus for kidney function analysis |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008538316A JP2008538316A (ja) | 2008-10-23 |
JP2008538316A5 JP2008538316A5 (ja) | 2009-10-01 |
JP5033789B2 true JP5033789B2 (ja) | 2012-09-26 |
Family
ID=37115492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008507811A Expired - Fee Related JP5033789B2 (ja) | 2005-04-19 | 2006-04-18 | 腎臓機能分析のための方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US8329143B2 (ja) |
EP (1) | EP1877104B1 (ja) |
JP (1) | JP5033789B2 (ja) |
CN (1) | CN101208109A (ja) |
AU (1) | AU2006236407B2 (ja) |
CA (1) | CA2649391C (ja) |
ES (1) | ES2413757T3 (ja) |
WO (1) | WO2006113724A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006236407B2 (en) | 2005-04-19 | 2011-04-28 | Indiana University Research And Technology Corporation | Method and apparatus for kidney function analysis |
US8591865B2 (en) | 2008-04-18 | 2013-11-26 | Pharmacophotonics, Inc. | Renal function analysis method and apparatus |
JP2011521899A (ja) * | 2008-04-18 | 2011-07-28 | ファーマコフォトニクス,インコーポレイティド | 腎機能の分析方法及び装置 |
IN2014DN06772A (ja) | 2012-02-17 | 2015-05-22 | Pharmacophotonics Inc | |
AU2014339082B2 (en) * | 2013-10-22 | 2018-11-08 | Jochen Friedemann | Improved transcutaneous organ function measurement |
CA3203465A1 (en) * | 2017-01-30 | 2018-08-02 | Medibeacon Inc. | Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflection corrections |
US20220068492A1 (en) * | 2019-01-14 | 2022-03-03 | Gynisus Inc. | System and method for selecting required parameters for predicting or detecting a medical condition of a patient |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280703B1 (en) | 1997-03-13 | 2001-08-28 | Mallinckrodt Inc. | Simultaneous multimodal measurement of physiological function |
US5928625A (en) | 1997-03-13 | 1999-07-27 | Mallinckrodt Inc. | Method of measuring physiological function |
ATE276745T1 (de) | 1998-04-09 | 2004-10-15 | Amersham Health As | Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter |
JP3948736B2 (ja) * | 2004-02-27 | 2007-07-25 | 旭化成メディカル株式会社 | 血液透析器 |
AU2006236407B2 (en) | 2005-04-19 | 2011-04-28 | Indiana University Research And Technology Corporation | Method and apparatus for kidney function analysis |
-
2006
- 2006-04-18 AU AU2006236407A patent/AU2006236407B2/en not_active Ceased
- 2006-04-18 US US11/911,895 patent/US8329143B2/en active Active
- 2006-04-18 ES ES06750582T patent/ES2413757T3/es active Active
- 2006-04-18 CN CNA2006800219493A patent/CN101208109A/zh active Pending
- 2006-04-18 WO PCT/US2006/014576 patent/WO2006113724A1/en active Application Filing
- 2006-04-18 JP JP2008507811A patent/JP5033789B2/ja not_active Expired - Fee Related
- 2006-04-18 CA CA2649391A patent/CA2649391C/en not_active Expired - Fee Related
- 2006-04-18 EP EP06750582A patent/EP1877104B1/en not_active Not-in-force
-
2012
- 2012-12-10 US US13/709,242 patent/US8741263B2/en active Active
-
2014
- 2014-04-16 US US14/253,949 patent/US9352054B2/en active Active
-
2016
- 2016-05-16 US US15/155,391 patent/US9744249B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20130101518A1 (en) | 2013-04-25 |
AU2006236407A1 (en) | 2006-10-26 |
WO2006113724A1 (en) | 2006-10-26 |
EP1877104A1 (en) | 2008-01-16 |
US9352054B2 (en) | 2016-05-31 |
US20090234205A1 (en) | 2009-09-17 |
ES2413757T3 (es) | 2013-07-17 |
CN101208109A (zh) | 2008-06-25 |
US8741263B2 (en) | 2014-06-03 |
EP1877104A4 (en) | 2011-06-29 |
JP2008538316A (ja) | 2008-10-23 |
US8329143B2 (en) | 2012-12-11 |
CA2649391C (en) | 2017-11-28 |
CA2649391A1 (en) | 2006-10-26 |
US20160256574A1 (en) | 2016-09-08 |
AU2006236407B2 (en) | 2011-04-28 |
EP1877104B1 (en) | 2013-03-13 |
US9744249B2 (en) | 2017-08-29 |
US20140227189A1 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9744249B2 (en) | Method and apparatus for kidney function analysis | |
US6594518B1 (en) | Device and method for classification of tissue | |
Ocak et al. | Monitoring microcirculation | |
Schriefl et al. | Etiologic classification of seizures, signalment, clinical signs, and outcome in cats with seizure disorders: 91 cases (2000–2004) | |
Friedland et al. | Measurement of mucosal capillary hemoglobin oxygen saturation in the colon by reflectance spectrophotometry | |
Shahzad et al. | Fluorescence spectroscopy: an emerging excellent diagnostic tool in medical sciences | |
US20210059582A1 (en) | Non-Invasive Glucose Monitoring by Raman Spectroscopy | |
EP2750605A1 (en) | System for non-invasive assay of liver funtion | |
JP2011516118A (ja) | グルコース以外の1つ以上の成分のスペクトルデータを使用して非侵襲で血糖を検出するための方法およびシステム | |
US20150185207A1 (en) | Quantifying Neutrophil Concentration in Blood | |
Sato et al. | Raman spectroscopy and its use for live cell and tissue analysis | |
US20190029637A1 (en) | A wearable sensor, and method, to monitor anti-coagulation therapy | |
Barshtein et al. | Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced | |
Vignal et al. | Measuring brain hemodynamic changes in a songbird: responses to hypercapnia measured with functional MRI and near-infrared spectroscopy | |
KR101725648B1 (ko) | 인도시아닌 그린을 이용하는 뇌허혈 질환의 광학 분석 방법 | |
Takihata et al. | In vivo diffuse reflectance spectroscopic analysis of fatty liver with inflammation in mice | |
JPH01158353A (ja) | 悪性高熱症の血液による診断法 | |
Nadeau et al. | Orthogonal polarization spectral imaging: state of the art | |
JP2023511740A (ja) | 腸透過性及び胃排出率を測定する方法 | |
RU2062046C1 (ru) | Способ комплексной проверки состояния здоровья | |
Dent | Plasma Volume Hematocrit (PVH):" Big Data" Applied to Physiology Enabled by a New Algorithm | |
CN115349827A (zh) | 一种光声成像监测酸碱失衡模型的建立方法 | |
TR2021006530A2 (tr) | Girişimsiz (Non-Invaziv) Kan Kalite Parametreleri Ölçüm Sistemi | |
JP2002085412A (ja) | 光測定方法及び光測定装置 | |
Vasudeva | Cytokine Dynamics, Diagnosis and Treatment of Neuroinflammation In Chronic Constriction Injury Rat Model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090417 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110823 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111130 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111226 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120106 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120612 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120702 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5033789 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |